A Single-Arm Phase II Clinical Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer
Latest Information Update: 19 Dec 2025
At a glance
- Drugs Trastuzumab rezetecan (Primary) ; Adebrelimab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Dec 2025 New trial record